What changed
A US federal grand jury indicted Swapandip Roy and Vicky Ramancha over an alleged scheme to obtain counterfeit Ozempic in China and sell it to US distributors at discounted prices between July 2023 and April 2024. Roy was extradited from Italy and pleaded not guilty; Ramancha remains at large. The charges include smuggling, selling counterfeit drugs and conspiracy to defraud the United States, carrying a potential combined sentence of 71 years if they are convicted.
Why it matters
The alleged fraud was designed to look legitimate. The products reportedly came with packaging, inserts, pen labels and needles intended to persuade buyers they were receiving authentic Ozempic, a drug that can cost patients hundreds of dollars each month.
That makes this more than a counterfeit-label case. It is an alleged attempt to pass fake medicine through the commercial chain that patients and distributors rely on. The FDA seized some of the products in December 2023 and issued a warning, but the alleged scheme continued afterward.
The allegations remain unproven in court, and it is not established whether any US patient was harmed or how widely the products circulated. Roy’s detention after an INTERPOL Red Notice and extradition from Italy, alongside the continuing search for Ramancha, shows the case now extends beyond the suspected sales network to an international enforcement effort.
Comments
No comments yet.